| Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies J Gauthier, ED Bezerra, AV Hirayama, S Fiorenza, A Sheih, CK Chou, ... Blood, The Journal of the American Society of Hematology 137 (3), 323-335, 2021 | 138 | 2021 |
| Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution JP Alderuccio, W Zhao, A Desai, N Gallastegui, J Ramdial, E Kimble, ... Journal of clinical oncology 36 (34), 3370-3380, 2018 | 74 | 2018 |
| Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients JF Camargo, E Kimble, R Rosa, LA Shimose, MX Bueno, N Jeyakumar, ... Biology of Blood and Marrow Transplantation 24 (4), 806-814, 2018 | 62 | 2018 |
| Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation JF Camargo, ED Wieder, E Kimble, CL Benjamin, DS Kolonias, D Kwon, ... Blood, The Journal of the American Society of Hematology 133 (8), 867-877, 2019 | 57 | 2019 |
| Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy N Gazeau, EC Liang, JM Voutsinas, P Barba, G Iacoboni, M Kwon, ... Transplantation and cellular therapy 29 (7), 430-437, 2023 | 40 | 2023 |
| Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation JP Alderuccio, W Zhao, A Desai, J Ramdial, N Gallastegui, E Kimble, ... American journal of hematology 94 (5), 585-596, 2019 | 31 | 2019 |
| Resolution of fibrinogen deficiency in a patient with congenital afibrinogenemia after liver transplantation. N Gallastegui, EL Kimble, TJ Harrington Haemophilia 22 (1), 2016 | 14 | 2016 |
| Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma AV Hirayama, EL Kimble, JH Wright, S Fiorenza, J Gauthier, JM Voutsinas, ... Blood Advances 8 (2), 453-467, 2024 | 7 | 2024 |
| Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL EC Liang, A Albittar, JJ Huang, AV Hirayama, EL Kimble, AJ Portuguese, ... Blood Advances 7 (22), 6990-7005, 2023 | 6 | 2023 |
| Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients JF Camargo, AD Anderson, R Rosa, E Kimble, KV Komanduri, MI Morris Transplant Infectious Disease 21 (2), e13054, 2019 | 6 | 2019 |
| Timing of PD-L1 blockade with durvalumab may affect outcomes of CD19 CAR-T cell therapy for relapsed/Refractory large B-Cell lymphoma A Vinaud Hirayama, S Fiorenza, J Gauthier, JM Voutsinas, QV Wu, ... Blood 140 (Supplement 1), 7447-7449, 2022 | 4 | 2022 |
| Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults EL Kimble, RD Cassaday Leukemia & Lymphoma 62 (14), 3333-3347, 2021 | 4 | 2021 |
| Anakinra for refractory CRS or ICANS after CAR T-cell therapy N Gazeau, EC Liang, JM Voutsinas, P Barba, G Iacoboni, M Kwon, ... Transplantation and cellular therapy 29 (7), 430, 2023 | 3 | 2023 |
| A novel GAB2::BRAF fusion in cutaneous non‐Langerhans‐cell histiocytosis with systemic involvement B Wu, EQ Konnick, EL Kimble, PC Hendrie, MM Shinohara, AS Moshiri Journal of Cutaneous Pathology 49 (8), 727-730, 2022 | 3 | 2022 |
| Outcomes in patients with marginal zone lymphomas undergoing transformation to high-grade lymphomas. JP Alderuccio, A Desai, N Gallastegui Crestani, J Ramdial, EL Kimble, ... Journal of Clinical Oncology 36 (15_suppl), 7559-7559, 2018 | 3 | 2018 |
| Safety of high-dose melphalan (200 Mg/M2) as conditioning for autologous stem cell transplantation for myeloma in elderly patients A Desai, A Beitinjaneh, J Ramdial, R Ali, L Lekakis, D Pereira, E Kimble, ... Biology of Blood and Marrow Transplantation 23 (3), S133-S134, 2017 | 3 | 2017 |
| Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity AJ Portuguese, A Albittar, JJ Huang, EC Liang, N Wuliji, M Taheri, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | 2 | 2024 |
| CAR T-cell therapy for relapsed or refractory large B-cell lymphoma using a fully human CD19-targeted single chain variable fragment: results of a first-in-human phase I/II study N Gazeau, S Fiorenza, EL Kimble, A Vinaud Hirayama, BS Pender, HA Di, ... Blood 140 (Supplement 1), 10363-10365, 2022 | 2 | 2022 |
| Functional Signatures Revealed by Deep Phenotyping of CMV-Specific CD8+ T Cells Predict Risk of Early CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation JF Camargo, E Wieder, E Kimble, CL Benjamin, D Kolonias, G Bravo, ... Biology of Blood and Marrow Transplantation 24 (3), S99, 2018 | 2 | 2018 |
| Materials and methods for subjects at risk for viral reactivation K Komanduri, E Wieder, J Camargo, E Kimble US Patent 11,913,962, 2024 | 1 | 2024 |
